FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...
Cancer
CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors
Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...
Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...
Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...
Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...
Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...
FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC
US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...
Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...
Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...
Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...
Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...
Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...
Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...
HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...